CLOCK and Alzheimer disease: The authors of this study, therefore, envisage miRNA-based therapies to regulate circadian rhythms and hippocampal signaling pathways in AD, whereby the daily mid-afternoon administration of a miR-16 mimic with a short half-life degrades CLOCK mRNA transcripts (which are increased in AD), reducing their cellular concentration.